Posttransplantation lymphoproliferative disorders

Pediatric Clinics of North America

Volumn 50, Issue 6, 2003, Pages 1471-1491

  Green, Michael ^a   Webber, Steven ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

BURKITT LYMPHOMA; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; LYMPHOPROLIFERATIVE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; REVIEW; TREATMENT PLANNING;

EID: 0346365439     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(03)00127-5     Document Type: Review

References (41)

1. Starzl TE. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula [discussion]. Ann Surg 1968;168:416.
2. Briggs JD, Hamilton DNH, Macsween RNM, et al. Infectious mononucleosis, herpes simplex infection and diffuse lymphoma in a renal transplant patient. Transplantation 1978;25:227.
3. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc 1995;27:38-40.
4. Chadburn A, Cesarman E, Knowles DM. Molecular pathology of posttransplant lymphoproliferative disorders. Semin Diagn Pathol 1997;14:15-26.
5. Webber SA. Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation? [Editorial] Pediatr Transplant 1999;3:95-9.
6. Zangwill SD, Hsu DT, Kichuk MR, et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant 1998;17:1161-6.
7. Finn L, Reyes J, Bueno J, Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998;22:299-309.
8. Cen H, Breinig MC, Atchison RW, Ho M, McKnight JLC. Epstein-Barr virus transmission via the donor organ in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4. J Virol 1991;65:976-80.
9. Haque T, Thomas JA, Falk KI, et al. Transmission of Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996;77:1169-72.
10. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990;323:1723-8.
11. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996;62:370-5.
12. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disease in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
13. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant recipients in the new immunosuppressive era. Clin Transplant 1997;11:243-9.
14. Webber SA. Fifteen years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. Pediatr Transplant 1997;1:8-21.
15. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American pediatric renal transplant cooperative study. Pediatr Transplant 2002;6:396-9.
16. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999;68:1851-4.
17. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000;70:94-9.
18. Harwood JS, Gould FK, McMaster A, et al. Significance of EBV status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation. Pediatr Transplant 1999;3:100-3.
19. Boyle GJ, Michaels MG, Webber SA, et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997;131:309-13.
20. Sweet SC, Spray TL, Huddleston CB, et al. Pediatric lung transplantation at St. Louis Children's Hospital, 1990-1995. Am J Respir Crit Care Med 1997;155:1027-35.
21. Green M, Reyes J, Webber S, Michaels MG, Rowe D. The role of the Epstein-Barr viral load in the diagnosis, management and possible prevention of EBV-associated post-transplant lymphoproliferative disease following solid organ transplantation. Curr Opin Organ Transplant 1999;4:292-6.
22. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant recipients with lymphoproliferative disorders. J Clin Microbiol 1997;35:1612-5.
23. Harris NL, Ferry JA, Swerdlow SH. Post-transplant lymphoproliferative disorders: summary of society for hematopathology work shop. Semin Diagn Pathol 1997;14:8-14.
24. Nalesnik MA, Starzl TE. Epstein-Barr virus, infectious mononucleosis, and post-transplant lymphoproliferative disorders. Transplant Sci 1994;4:61-79.
25. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood 1995;85:552-65.
26. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth muscle tumors occurring after organ transplantation. N Engl J Med 1995;332:19-25.
27. Epstein MA, Morgan AJ, Finerty S, et al. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985;318:287-9.
28. Green M, Reyes J, Rowe D. New strategies in the prevention and management of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantation. Current Opinion in Organ Transplantation 1998;3:143-7.
29. Abedi MR, Linde A, Christensson B, Mackett M, Hammarstrom L, Smith C. Preventive effect of IgG from EBV-seropositive donors on the development of human lymphoproliferative disease in SCID mice. Int J Cancer 1997;71:624-9.
30. Green M, Michaels MG, Webber SA, Rowe D, Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients. Pediatr Transplant 1999;3:271-81.
31. Webber SA, Green M. Post-transplant lymphoproliferative disorders: advances in diagnosis, prevention and management in children. Prog Pediatr Cardiol 2000;11:145-57.
32. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-7.
33. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus induced B-cell lymphoma after renal transplantation. N Engl J Med 1982;306:913-8.
34. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gamma globulin [letter]. N Engl J Med 1988;318:1334.
35. Ippoliti G, Martinelli L, Loernzutti F, et al. Post-transplant lymphoproliferative disease after heart transplantation on sandimmune therapy: treatment with interferon-alpha 2b and intravenous immunoglobulin. Transplant Proc 1995;26:2660-1.
36. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
37. Fisher A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-6.
38. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(suppl 1):113-6.
39. Webber SA, Hayashi R, Harmon W, et al. Anti-CD 20 monoclonal antibody for pediatric posttransplant lymphoproliferative disorders: follow-up of a multi-center experience [abstract]. Pediatr Transplant 2003;7(suppl 4):89.
40. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet 1995;345:9-13.
41. Gross TG. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Advances in Cancer Research 2002;159:96-103.